close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Candidates for SYNVISC®

While proven effective in all stages of osteoarthritis (OA) of the knee, some studies have shown that SYNVISC was most effective when used in patients with earlier stage disease. But how do you know when SYNVISC is the next step?

SYNVISC may be appropriate treatment for your patients who:

  • Receive inadequate knee pain relief from exercise, physical therapy, and lifestyle changes
  • Receive inadequate relief from acetaminophen, NSAIDs, or COX-2 inhibitors
  • Are not yet appropriate candidates for knee surgery

The only 3-injection viscosupplement that can reduce or eliminate OA knee pain 1 for up to 6 months, SYNVISC has proven to be as effective as NSAIDS, without the risk of gastric side effects 2 —and more effective long term than intra-articular corticosteroids. 3




Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)